In Brief: Daiichi
Executive Summary
Daiichi: Japanese company files its first NDA in U.S. on Dec. 18 for ofloxacin otic solution for the indications of otitis externa in adults and children, chronic suppurative otitis media in adolescents and adults with perforated tympanic membranes, and acute otitis media in children with tympanostomy tubes. On Dec. 23, Daiichi filed a computer-assisted NDA for the indications...